Biomunex Pharmaceuticals
96bis Boulevard Raspail
Paris
75006
France
Website: http://www.biomunex.com/
Email: contact@biomunex.com
About Biomunex Pharmaceuticals
Biomunex is a biopharmaceutical company focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs in the treatment of cancer.YEAR FOUNDED:
2014
LEADERSHIP:
Founder and CEO: Dr. Pierre-Emmanuel Gerard
CSO: Dr. Eugene Zhukovsky
CAREER:
Please click here for Biomunex's job opportunities.
TECHNOLOGY & Products:
Please click here for Biomunex's technology.
7 articles about Biomunex Pharmaceuticals
-
Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology
3/4/2024
Biomunex Pharmaceuticals announced the signature of an exclusive license and exploitation agreement with Institut Curie.
-
Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
1/24/2024
This first-in-man trial conducted by Onward Therapeutics, under the license and co-development agreement, is a Phase 1 clinical trial for the evaluation of a bispecific antibody generated from Biomunex' proprietary BiXAb® platform.
-
Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting
4/12/2023
Biomunex Pharmaceuticals announced today that it will participate in and present new scientific data at the American Association for Cancer Research (AACR) annual meeting, which will take place from April 14th to April 19th, 2023 at the Orange County Convention Center, Orlando, Florida.
-
Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
2/16/2021
Onward Therapeutics SA announced the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS, Paris, France, of a bispecific antibody targeting two immune checkpoints.
-
Biomunex Pharmaceuticals Establishes US Subsidiary
5/28/2019
Biomunex Inc. to focus on R&D and business development activities in the US
-
Biomunex Pharmaceuticals signs a licensing agreement with Sanofi for the development of bi- and multi-specific antibodies
1/15/2019
Under the terms of the agreement, Sanofi will have access to Biomunex' proprietary technology to generate and optimize bi- and multi-specific antibody therapeutics.
-
Biomunex Appoints Dr. Sebastian Amigorena And Dr. Dragan Grabulovski As Key Scientific And Strategic Advisors
12/5/2016